108 results
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
1 Jul 20
Last of 12,400 Participants Completes Final Visit in BiondVax’s M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
8:19am
illness and 650,000 deaths.2 In addition, pandemic influenza, such as the H1N1 Swine Flu pandemic of 2009, is a constant global threat. However, current … , as well as emerging pandemic strains.
Dr. Tamar Ben-Yedida, BiondVax’s Chief Scientist, commented, “We are pleased that despite the ongoing COVID-19
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
1 Sep 20
Report of Foreign Private Issuer
7:18am
of the 4 drawdowns; Variable remuneration based on royalties of net sales Pioneering a revolutionary approach for protection against seasonal & pandemic … the Impact of Pandemic Influenza through Vaccine Innovation, September 2019 | 5. https://www.cdc.gov/flu/about/burden/index.html VAST UNMET NEED 1
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
19 Mar 20
BiondVax’s CEO Comments on Impact of COVID-19 Pandemic on the Company’s Ongoing Phase 3 Clinical Trial
1:05pm
Exhibit 99.1
BiondVax’s CEO Comments on Impact of COVID-19 Pandemic on the Company’s Ongoing Phase 3 Clinical Trial
Jerusalem, Israel – March 19 … , 2020 –BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal
6-K
SCNI
Scinai Immunotherapeutics Ltd
30 Apr 20
Report of Foreign Private Issuer
9:39am
pandemic, the Company intends to include the following Risk Factor in its Report, which may be updated to reflect events subsequent to the date … COVID-19 virus as a pandemic and many countries, including the U.S., Israel, Japan and certain states in Europe have imposed various measures designed
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
23 Oct 20
BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate
10:59am
protection against current, future, seasonal and pandemic influenza, today announced topline data from the Company’s pivotal, phase 3 clinical trial of M-001 … protection against current and future, seasonal and pandemic influenza. An NIH/NIAID Phase 2 study completed in 2020 showed a significant increase
6-K
EX-99.1
z3k5x6jbhr jiy
22 Apr 19
Report of Foreign Private Issuer
10:03am
6-K
EX-99.1
kqm 3dtwg2tkum27
8 Apr 19
Report of Foreign Private Issuer
7:00am
6-K
EX-99.1
2tk4kd0
4 May 20
BiondVax Announces Upcoming Expiration of Public Warrants
10:48am
6-K
EX-99.1
w7fci4xzm705zd
20 May 20
BiondVax Announces Receipt of $4.2 million through Exercise of Warrants
7:43am
6-K
EX-99.1
1xdy9zmh1v
23 Mar 21
Current Report
7:54am
6-K
EX-99.1
zb5 p50jl7woix03fd
2 Oct 20
Condensed Interim Financial Statements
12:00am
6-K
EX-99.2
94v7w5xw7
28 Jan 21
BiondVax Announces Third Quarter 2020 Financial Results & Business Update
5:25pm
6-K
EX-99.1
w69kpcf0uspg5bcy
17 Aug 20
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
6:12am
6-K
EX-99.1
nyvjq 8yioi27t
1 Jul 20
BiondVax Announces First Quarter 2020 Financial Results
6:14am
6-K
EX-99.1
ng4zwfnzdskvejn
28 Jun 18
Corporate Biotech Executive Mark Germain Joins BiondVax’s Board of Directors
9:20am
6-K
EX-99.1
n8pu3 n0cvlb
11 Feb 21
BiondVax Announces Exercise in Full of Underwriter’s Over-Allotment Option in Follow-on Offering
6:30am
6-K
EX-99.1
ry0aye732gu
2 Feb 21
BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering
4:36pm
6-K
EX-99.1
9v74lr5d
18 Jun 19
Patent Covering Manufacturing Process of BiondVax’s M-001 Universal Flu Vaccine Allowed in USA and Japan
9:23am
6-K
EX-99.1
d6v4404wr dw
24 Aug 20
BiondVax Announces Second Quarter 2020 Financial Results
6:11am
6-K
EX-99.1
esf7aubhpwphma8oac
29 Oct 18
BiondVax’s Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season’s Enrollment of 4,098 Participants
6:18am